Literature DB >> 18829544

Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines.

Marie Jaksch1, Jorge Múnera, Ruchi Bajpai, Alexey Terskikh, Robert G Oshima.   

Abstract

CD133 (Prominin1) is a pentaspan transmembrane glycoprotein expressed in several stem cell populations and cancers. Reactivity with an antibody (AC133) to a glycoslyated form of CD133 has been widely used for the enrichment of cells with tumor-initiating activity in xenograph transplantation assays. We have found by fluorescence-activated cell sorting that increased AC133 reactivity in human embryonic stem cells, colon cancer, and melanoma cells is correlated with increased DNA content and, reciprocally, that the least reactive cells are in the G(1)-G(0) portion of the cell cycle. Continued cultivation of cells sorted on the basis of high and low AC133 reactivity results in a normalization of the cell reactivity profiles, indicating that cells with low AC133 reactivity can generate highly reactive cells as they resume proliferation. The association of AC133 with actively cycling cells may contribute to the basis for enrichment for tumor-initiating activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829544      PMCID: PMC2561223          DOI: 10.1158/0008-5472.CAN-08-0723

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Analysis of primitive CD34- and CD34+ hematopoietic cells from adults: gain and loss of CD34 antigen by undifferentiated cells are closely linked to proliferative status in culture.

Authors:  Douglas C Dooley; Barbara K Oppenlander; Mang Xiao
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

2.  A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.

Authors:  S Miraglia; W Godfrey; A H Yin; K Atkins; R Warnke; J T Holden; R A Bray; E K Waller; D W Buck
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

3.  The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions.

Authors:  D Corbeil; K Röper; A Hellwig; M Tavian; S Miraglia; S M Watt; P J Simmons; B Peault; D W Buck; W B Huttner
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

4.  Reversible expression of CD34 by murine hematopoietic stem cells.

Authors:  T Sato; J H Laver; M Ogawa
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

5.  Cell cycle analysis of the CD133+ and CD133- cells isolated from umbilical cord blood.

Authors:  Branka Grskovic; Katharina Ruzicka; Alireza Karimi; Durdi Qujeq; Mathias M Müller
Journal:  Clin Chim Acta       Date:  2004-05       Impact factor: 3.786

6.  CD133, a novel marker for human prostatic epithelial stem cells.

Authors:  Gavin D Richardson; Craig N Robson; Shona H Lang; David E Neal; Norman J Maitland; Anne T Collins
Journal:  J Cell Sci       Date:  2004-06-29       Impact factor: 5.285

7.  Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis.

Authors:  Anmol Chandele; Vandna Prasad; Jayashree C Jagtap; Ravi Shukla; Padma R Shastry
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

8.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

9.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.

Authors:  Sergey V Shmelkov; Jason M Butler; Andrea T Hooper; Adilia Hormigo; Jared Kushner; Till Milde; Ryan St Clair; Muhamed Baljevic; Ian White; David K Jin; Amy Chadburn; Andrew J Murphy; David M Valenzuela; Nicholas W Gale; Gavin Thurston; George D Yancopoulos; Michael D'Angelica; Nancy Kemeny; David Lyden; Shahin Rafii
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

10.  Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation.

Authors:  Ichiro Nakano; Andres A Paucar; Ruchi Bajpai; Joseph D Dougherty; Amani Zewail; Theresa K Kelly; Kevin J Kim; Jing Ou; Matthias Groszer; Tetsuya Imura; William A Freije; Stanley F Nelson; Michael V Sofroniew; Hong Wu; Xin Liu; Alexey V Terskikh; Daniel H Geschwind; Harley I Kornblum
Journal:  J Cell Biol       Date:  2005-08-01       Impact factor: 10.539

View more
  46 in total

1.  Integrin alpha 6 regulates glioblastoma stem cells.

Authors:  Justin D Lathia; Joseph Gallagher; John M Heddleston; Jialiang Wang; Christine E Eyler; Jennifer Macswords; Qiulian Wu; Amit Vasanji; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2010-05-07       Impact factor: 24.633

2.  CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.

Authors:  Anthony B Mak; Kim M Blakely; Rashida A Williams; Pier-Andrée Penttilä; Andrey I Shukalyuk; Khan T Osman; Dahlia Kasimer; Troy Ketela; Jason Moffat
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

3.  Proliferation characteristics of CD133+ cell population in colorectal cancer.

Authors:  Dongdong Yu; Yonghong Zhang; You Zou; Jichao Qin; Xiaolan Li; Hui Xiao; Deding Tao; Junbo Hu; Jianping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 4.  Cancer stem cells, cancer cell plasticity and radiation therapy.

Authors:  Erina Vlashi; Frank Pajonk
Journal:  Semin Cancer Biol       Date:  2014-07-12       Impact factor: 15.707

5.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

Authors:  Eli E Bar; Alex Lin; Vasiliki Mahairaki; William Matsui; Charles G Eberhart
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

6.  Expression of CD133 in SW620 colorectal cancer cells is modulated by the microenvironment.

Authors:  Zhili Yang; Zhigang Wang; Youben Fan; Qi Zheng
Journal:  Oncol Lett       Date:  2012-04-24       Impact factor: 2.967

Review 7.  The therapeutic promise of the cancer stem cell concept.

Authors:  Natasha Y Frank; Tobias Schatton; Markus H Frank
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

8.  Cancer stem cells in solid tumors: elusive or illusive?

Authors:  Yvonne Welte; James Adjaye; Hans R Lehrach; Christian Ra Regenbrecht
Journal:  Cell Commun Signal       Date:  2010-05-11       Impact factor: 5.712

Review 9.  Cancer stem cells: cell culture, markers, and targets for new therapies.

Authors:  Candace A Gilbert; Alonzo H Ross
Journal:  J Cell Biochem       Date:  2009-12-01       Impact factor: 4.429

10.  Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.

Authors:  Chun-Yan Li; Bao-Xiu Li; Yi Liang; Rui-Qing Peng; Ya Ding; Da-Zhi Xu; Xin Zhang; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Feng Zhu; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-07-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.